ClinicalTrials.gg

Program

LY4515100

A development code. Also written as “LY4515100 via SAD”, “LY4515100 via MAD” and “[¹⁴C]-LY4515100 Oral Solution”.

In Eli Lilly's pipeline, Nav1.8 inhibitor. Its studies are mostly in Acute Pain, led by Eli Lilly.

Furthest: phase 2, since Mar 30, 20263 company-led studies, 3 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly33 open or runningphase 2since Mar 30, 2026Jan 6, 2026Nov 2026phase 2 · NCT07511816
  • Named in Eli Lilly’s own pipeline as Nav1.8 Inhibitor (SM), phase 2, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 6, 2026First study: phase 1 study in HealthyFirst studyNCT07339722 · 209 planned · United States
  2. Mar 30, 2026Phase 2 study in Acute PainPhase 2 reachedNCT07511816 · 212 planned · United States
  3. Oct 5, 2026Phase 1 study in HealthyNCT07867327 · 16 planned · United States

Ahead

  1. Nov 2026Primary completion: phase 2 study in Acute PainNCT07511816
  2. Dec 2026Primary completion: phase 1 study in HealthyNCT07867327
  3. Mar 2027Primary completion: phase 1 study in HealthyNCT07339722

TargetBeta

“Nav1.8 inhibitor”the company's pipeline, read by Claude · source

Other programs on SCN10A

ProgramCompanyFurthest phaseStudies
LidocaineruleKeenova Therapeuticsphase 463
LamotrigineruleGlaxoSmithKlinephase 461
Carbamazepinerulegrin-therapeutics-incphase 421
DronedaroneruleSanofiphase 418
chloroprocainerulesintetica-saphase 48
RiluzoleruleSanofiphase 46
PrilocaineruleHaisco Pharmaceutical Groupphase 42
CarticaineruleLaboratoires Theaphase 41
Ropivacainerulepainreform-ltdphase 317
PhenytoinruleViatrisphase 310
rufinamideruleEisaiphase 37
HRS-2129Jiangsu HengRui Medicinephase 37

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07867327Healthy · United States1Not yet recruitingDec 202616
NCT07511816Acute Pain · United States2RecruitingNov 2026212
NCT07339722Healthy · United States1RecruitingMar 2027209

How it is read

Names in the registry

  • “LY4515100”, 2 entries
  • “LY4515100 via SAD”, 1 entry
  • “LY4515100 via MAD”, 1 entry
  • “[¹⁴C]-LY4515100 Oral Solution”, 1 entry
  • “LY4515100 Tablet”, 1 entry

Codes read as this program: LY4515100.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.